Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
ARA-290
Repair & Recovery
Molecular Dossier
- Rank Index: 24
- Status: Phase 2 Clinical
- What does this mean?
- Molecular Structure: C51H78N16O21 (Pyroglutamate helix B surface peptide)
About ARA-290
11-amino-acid peptide derived from erythropoietin; selectively activates the Innate Repair Receptor (IRR) to mitigate neuropathic pain and inflammation.
Clinical Focus
Neuropathic Pain Repair
Archival Aliases
Cibinetide, pHBSP
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
How does ARA-290 (Cibinetide) protect small nerve fibers without affecting red blood cells?
ARA-290 is a cyclic peptide derived from erythropoietin (EPO) that selectively binds to the Innate Repair Receptor (IRR). Unlike EPO, it does not bind to the classical EPO receptor homodimer, meaning it provides potent anti-inflammatory and neuroprotective effects without the risk of increasing hematocrit or red blood cell count.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | C51H78N16O21 (Pyroglutamate helix B surface peptide) |
| Primary Pathway | Repair & Recovery |
| Research Phase | Phase 2 Clinical |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-04-10